Changed endpoints cannot save Proteon from becoming a shell - Vantage

Changed endpoints cannot save Proteon from becoming a shell  Vantage

The tried and tested biotech strategy of finding a new endpoint to follow after a clinical trial failure has not worked for Proteon Therapeutics. The group's lead ...



Comments

Post a Comment

Popular posts from this blog

Orchestra BioMed™ Announces FDA Breakthrough Device Designation for Virtue® Sirolimus-Eluting Balloon for Treatment of Below-the-Knee Peripheral Artery Disease - Vascular Disease Management

Orchestra BioMed™ Announces FDA Breakthrough Device Designation for Virtue® Sirolimus-Eluting Balloon for Treatment of Below-the-Knee Peripheral Artery Disease    Vascular Disease Management First and only non-coated sirolimus-eluting angioplasty balloon system to receive Breakthrough Device designation for below-the-knee disease; Follows ...
Read more